Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial - 04/02/16
, Leena Gandhi, MD b, Shirish Gadgeel, ProfMD c, Gregory J Riely, MD d, Jeremy Cetnar, MD e, Howard West, MD f, D Ross Camidge, MD g, Mark A Socinski, ProfMD h, Alberto Chiappori, MD i, Tarek Mekhail, MD j, Bo H Chao, MD k, Hossein Borghaei, DO l, Kathryn A Gold, MD m, Ali Zeaiter, MD n, Walter Bordogna, PhD n, Bogdana Balas, MD n, Oscar Puig, PhD n, Volkmar Henschel, PhD n, Sai-Hong Ignatius Ou, ProfMD oon behalf of the
study investigators†
Summary |
Background |
Alectinib—a highly selective, CNS-active, ALK inhibitor—showed promising clinical activity in crizotinib-naive and crizotinib-resistant patients with ALK-rearranged (ALK-positive) non-small-cell lung cancer (NSCLC). We aimed to assess the safety and efficacy of alectinib in patients with ALK-positive NSCLC who progressed on previous crizotinib.
Methods |
We did a phase 2 study at 27 centres in the USA and Canada. We enrolled patients aged 18 years or older with stage IIIB–IV, ALK-positive NSCLC who had progressed after crizotinib. Patients were treated with oral alectinib 600 mg twice daily until progression, death, or withdrawal. The primary endpoint was the proportion of patients achieving an objective response by an independent review committee using Response Evaluation Criteria in Solid Tumors, version 1.1. Response endpoints were assessed in the response-evaluable population (ie, patients with measurable disease at baseline who received at least one dose of study drug), and efficacy and safety analyses were done in the intention-to-treat population (all enrolled patients). This study is registered with ClinicalTrials.gov, number NCT01871805. The study is ongoing and patients are still receiving treatment.
Findings |
Between Sept 4, 2013, and Aug 4, 2014, 87 patients were enrolled into the study (intention-to-treat population). At the time of the primary analysis (median follow-up 4·8 months [IQR 3·3–7·1]), 33 of 69 patients with measurable disease at baseline had a confirmed partial response; thus, the proportion of patients achieving an objective response by the independent review committee was 48% (95% CI 36–60). Adverse events were predominantly grade 1 or 2, most commonly constipation (31 [36%]), fatigue (29 [33%]), myalgia 21 [24%]), and peripheral oedema 20 [23%]). The most common grade 3 and 4 adverse events were changes in laboratory values, including increased blood creatine phosphokinase (seven [8%]), increased alanine aminotransferase (five [6%]), and increased aspartate aminotransferase (four [5%]). Two patients died: one had a haemorrhage (judged related to study treatment), and one had disease progression and a history of stroke (judged unrelated to treatment).
Interpretation |
Alectinib showed clinical activity and was well tolerated in patients with ALK-positive NSCLC who had progressed on crizotinib. Therefore, alectinib could be a suitable treatment for patients with ALK-positive disease who have progressed on crizotinib.
Funding |
F Hoffmann-La Roche.
Le texte complet de cet article est disponible en PDF.Plan
Vol 17 - N° 2
P. 234-242 - février 2016 Retour au numéro
Article précédent
- Hyperbaric oxygen for patients with chronic bowel dysfunction after pelvic radiotherapy (HOT2): a randomised, double-blind, sham-controlled phase 3 trial
- Mark Glover, Gary R Smerdon, H Jervoise Andreyev, Barbara E Benton, Pieter Bothma, Oliver Firth, Lone Gothard, John Harrison, Mihaela Ignatescu, Gerard Laden, Sue Martin, Lauren Maynard, Des McCann, Christine E L Penny, Spencer Phillips, Grace Sharp, John Yarnold
- Addition of docetaxel or bisphosphonates to standard of care in men with localised or metastatic, hormone-sensitive prostate cancer: a systematic review and meta-analyses of aggregate data
- Claire L Vale, Sarah Burdett, Larysa H M Rydzewska, Laurence Albiges, Noel W Clarke, David Fisher, Karim Fizazi, Gwenaelle Gravis, Nicholas D James, Malcolm D Mason, Mahesh K B Parmar, Christopher J Sweeney, Matthew R Sydes, Bertrand Tombal, Jayne F Tierney, STOpCaP Steering Group
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?